» Articles » PMID: 37308727

Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage

Overview
Journal Neurocrit Care
Specialty Critical Care
Date 2023 Jun 12
PMID 37308727
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nimodipine is recommended to prevent delayed cerebral ischemia in patients with spontaneous subarachnoid hemorrhage (SAH). Here, we studied hemodynamic side effects of different nimodipine formulations (per os [PO] and intravenous [IV]) in patients with SAH undergoing continuous blood pressure monitoring.

Methods: This observational cohort study includes consecutive patients with SAH (271 included in the IV group, 49 in the PO group) admitted to a tertiary care center between 2010 and 2021. All patients received prophylactic IV or PO nimodipine. Hemodynamic responses were evaluated based on median values within the first hour after continuous IV nimodipine initiation or PO nimodipine application (601 intakes within 15 days). Significant changes were defined as > 10% drop in systolic blood pressure (SBP) or diastolic blood pressure from baseline (median values 30 min before nimodipine application). With the use of multivariable logistic regression, risk factors associated with SBP drops were identified.

Results: Patients were admitted with a median Hunt & Hess score of 3 (2-5; IV 3 [2-5], PO 1 [1-2], p < 0.001) and were 58 (49-69) years of age. Initiation of IV nimodipine was associated with a > 10% SBP drop in 30% (81/271) of patients, with a maximum effect after 15 min. A start or increase in noradrenaline was necessary in 136/271 (50%) patients, and colloids were administered in 25/271 (9%) patients within 1 h after IV nimodipine initiation. SBP drops > 10% occurred after 53/601 (9%) PO nimodipine intakes, with a maximum effect after 30-45 min in 28/49 (57%) patients. Noradrenaline application was uncommon (3% before and 4% after nimodipine PO intake). Hypotensive episodes to an SBP < 90 mm Hg were not observed after IV or PO nimodipine application. In multivariable analysis, only a higher SBP at baseline was associated with a > 10% drop in SBP after IV (p < 0.001) or PO (p = 0.001) nimodipine application, after adjusting for the Hunt & Hess score on admission, age, sex, mechanical ventilation, days after intensive care unit admission, and delayed cerebral ischemia.

Conclusions: Significant drops in SBP occur in one third of patients after the start of IV nimodipine and after every tenth PO intake. Early recognition and counteracting with vasopressors or fluids seems necessary to prevent hypotensive episodes.

Citing Articles

Description of STRIVE-ON Study Protocol: Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Phase....

Choi A, Chou S, Ducruet A, Kimberly W, Loch Macdonald R, Rabinstein A Neurocrit Care. 2025; .

PMID: 39875683 DOI: 10.1007/s12028-024-02207-8.


Causal Relationship Between the Abuse of Cholesterol-Lowering Medication, Blood Pressure Medication, Insulin, and Exogenous Hormones and Cerebral Infarction.

Liu J, Lv D, Li S, An Z, He Z, Liu Y Brain Behav. 2024; 14(12):e70186.

PMID: 39710996 PMC: 11663836. DOI: 10.1002/brb3.70186.


Nimodipine in Aneurysmal Subarachnoid Hemorrhage: Are Old Data Enough to Justify Its Current Treatment Regimen?.

Llompart-Pou J, Perez-Barcena J, Godoy D Neurocrit Care. 2024; .

PMID: 39690377 DOI: 10.1007/s12028-024-02182-0.


Ultrasound-Induced Release Profile of Nimodipine from Drug-Loaded Block Copolymers after Singular vs. Repeated Sonication: In Vitro Analysis in Artificial Cerebrospinal Fluid.

Doring K, Sperling S, Ninkovic M, Lanfermann H, Streit F, Fischer A Brain Sci. 2024; 14(9).

PMID: 39335407 PMC: 11430527. DOI: 10.3390/brainsci14090912.


Contemporary management of aneurysmal subarachnoid haemorrhage. An update for the intensivist.

Robba C, Busl K, Claassen J, Diringer M, Helbok R, Park S Intensive Care Med. 2024; 50(5):646-664.

PMID: 38598130 PMC: 11078858. DOI: 10.1007/s00134-024-07387-7.


References
1.
Claassen J, Park S . Spontaneous subarachnoid haemorrhage. Lancet. 2022; 400(10355):846-862. PMC: 9987649. DOI: 10.1016/S0140-6736(22)00938-2. View

2.
Rass V, Helbok R . How to diagnose delayed cerebral ischaemia and symptomatic vasospasm and prevent cerebral infarction in patients with subarachnoid haemorrhage. Curr Opin Crit Care. 2021; 27(2):103-114. DOI: 10.1097/MCC.0000000000000798. View

3.
Connolly Jr E, Rabinstein A, Carhuapoma J, Derdeyn C, Dion J, Higashida R . Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012; 43(6):1711-37. DOI: 10.1161/STR.0b013e3182587839. View

4.
Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G . European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013; 35(2):93-112. DOI: 10.1159/000346087. View

5.
Geraldini F, De Cassai A, Diana P, Correale C, Boscolo A, Zampirollo S . A Comparison Between Enteral and Intravenous Nimodipine in Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis. Neurocrit Care. 2022; 36(3):1071-1079. DOI: 10.1007/s12028-022-01493-4. View